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Ventricular Remodeling
Fundamental to the Progression
(and Regression) of Heart Failure*
James E. Udelson, MD, Marvin A. Konstam, MD
Boston, Massachusetts
The ability of the left ventricle to adapt its structure and
function to prevailing conditions has long fascinated clini-
cians and investigators. The left ventricle has a truly
remarkable plasticity, evident from stresses both physiologic
and pathologic (1). The physiologic stress of high-level
athletic endeavors leads to chamber dilation and a degree of
hypertrophy (2), whereas more pathologic stress such as that
associated with volume overload from valvular regurgitation
can lead to a dramatic increase in cavity size (3). Almost as
remarkable is that these processes may be reversible when
the stress is removed or attenuated, with the left ventricle
capable of restoration of normal size and shape. As an
example, it has been well documented that after aortic valve
replacement for aortic regurgitation, if performed within a
certain time window, the left ventricle can demonstrate
substantial reversal of the dilation over months of follow-up
(4). Indeed, the concept of potential reversibility of this
adaptive process underlies recommendations for “decondi-
tioning” when a question arises about whether a hypertro-
phied left ventricle is secondary to athletic activity, in which
case the hypertrophy should regress or is a sign of hyper-
trophic cardiomyopathy, in which case, it should not (5).
See page 1468
Fundamental work on the changes in left ventricular
(LV) structure and function after the pathologic insult of a
myocardial infarction (MI) was reported by Pfeffer et al. (6)
many years ago. It is thought that the process of post-MI
remodeling, with chamber dilation and hypertrophy and
interstitial changes in remote myocardium, is initially adap-
tive in an attempt to maintain stroke volume in the face of
the loss of contractile elements, but becomes maladaptive
*Editorials published in the Journal of the American College of Cardiology reflect the
views of the authors and do not necessarily represent the views of JACC or the
American College of Cardiology.
From the Division of Cardiology and CardioVascular Center, Tufts Medical
Center and Tufts University School of Medicine, Boston, Massachusetts. Dr.
Udelson has received research funding from/served as a consultant to Otsuka, Pfizer,
and Medtronic. Dr. Konstam has received moderate support from Otsuka, Pfizer,
Johnson & Johnson, and Merck.over time, driven by neurohormonal activation. The initial
observations on the sequence of structural changes after an
infarct in an animal model were followed soon thereafter by
the demonstration that these changes were associated with
the risk of mortality after the MI (7).
Human studies subsequently documented many of the
same findings, and over the years, the knowledge in this area
has become more refined. Several studies documented that
measures of LV size and function early after an MI were
highly prognostic for outcomes (8,9). Moreover, particular
patterns of remodeling appear to confer distinct levels of risk
because post-MI patients with a pattern of concentric
hypertrophy appear to be at the highest risk, as seen in an
analysis from patients enrolled in a clinical trial (10).
Beyond the post-MI setting, similar concepts have been
demonstrated among patients with heart failure and reduced
systolic function. Measures of LV size or function at 1 time
point identify a group of patients at increased risk of a more
unfavorable outcome (11).
Longitudinal studies further illuminate the relationship
between LV remodeling and outcomes. Of great interest
was a secondary analysis of the SAVE (Survival and Ven-
tricular Enlargement) trial. In this study, the change in
measures of end-systolic and -diastolic volumes from base-
line to a follow-up time point was associated with an
unfavorable longer term course (12). This relationship
persisted after adjustment for treatment assignment, that is,
the data suggested that patients who remodeled while
taking the angiotensin-converting enzyme inhibitor capto-
pril were at higher risk than those taking placebo who did
not remodel.
The understanding that one of the main drivers of the
remodeling process, either in the post-MI setting or in
chronic heart failure, was neurohormonal activation, led to
intense interest in and investigation of the effects of neuro-
hormonal blockade on the processes and mechanisms of
remodeling and of course also the impact of neurohormonal
blockade on patient outcomes. Captopril was shown to
attenuate a progressive increase in LV volumes over a year of
therapy after an anterior MI (13), and enalapril was shown
to reduce volumes relative to placebo over a 3-year
follow-up in patients with chronic heart failure and systolic
dysfunction (14). Subsequently, large randomized, placebo-
controlled trials demonstrated favorable effects on long-
term mortality of captopril in patients with post-MI LV
dysfunction (15), and for enalapril in patients with chronic
heart failure and systolic dysfunction who had mild to
moderate symptoms (16). The findings that angiotensin-
converting enzyme inhibitors ameliorated or reversed the
remodeling process and also favorably affected mortality led
to the attractive supposition that LV remodeling was a
fundamental feature of the post-MI or chronic heart failure
disease process and its progression and that an intervention’s
effect on remodeling may act as a “surrogate” for the
intervention’s potential impact on outcome.
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Ventricular Remodeling March 29, 2011:1477–9In an analysis of the existing literature on the effects of
therapeutic interventions on LV remodeling and also on
mortality in patients with LV dysfunction, we recently
showed that there is a positive correlation between an
intervention’s effect on LV volumes and function and its
effect on mortality (17). The relationship does not rise to the
level where remodeling benefit may be considered a surro-
gate for survival, as has been strictly defined for trials or for
regulatory considerations. However, the data suggested that
an intervention’s short-term effect on LV remodeling could
be used as a probability signal for longer term therapeutic
effects on outcomes, and a modest benefit on survival may be
considered more conclusive when accompanied by a remod-
eling benefit. Recent examples of a “disconnect” in this
relationship include the effect of aldosterone antagonists in
patients with chronic heart failure and systolic dysfunction
and mild to moderate symptoms. A trial of 9 months of
therapy with eplerenone showed no effect on remodeling
(18), whereas favorable outcome effects were seen in the
recently published EMPHASIS-HF (Eplerenone in Mild
Patients Hospitalization and Survival Study in Heart Fail-
ure) trial (19). These data support the concept that the
progression of the disease state in the post-MI setting or in
chronic heart failure is unlikely to be characterized by a
single parameter such as remodeling and that outcome
predictions may best incorporate multiple elements.
An important limitation of the literature included in our
recent analysis as well as other observational data is that the
studies generally report the effect of a single intervention on
remodeling, whether it is a drug or a device, such as cardiac
resynchronization therapy. Evidence-based treatment of
patients with LV dysfunction is, of course, based on
multiple therapeutic approaches used together over time to
optimize outcomes. How does such a polytherapeutic ap-
proach affect the remodeling process, and what are the
implications for outcomes?
Into this void of information steps the study by Merlo et
al. (20), reported in this issue of the Journal. At a tertiary
referral center in Trieste, Italy, 361 patients with nonisch-
emic dilated cardiomyopathy were enrolled over 10 years
and were treated according to prevalent guidelines. Echo-
cardiography was performed at baseline and again at a mean
of approximately 2 years after the initial study. All patients
were followed for at least 10 years, a major strength of this
study. The investigators examined the relationship between
baseline variables and prognosis, as well as the relationship
between the change in selected variables (including the
remodeling data) and outcomes, from the time point of
re-evaluation onward. Reverse remodeling was arbitrarily
defined as an LV ejection fraction (EF) increase of 10 EF
units or an LVEF of 50% and a decrease in indexed LV
end-diastolic diameter of 10% or of 33 mm/m2. Ap-
roximately one-third of the patients met this definition. Of
nterest was that 1 of the predictors of reverse remodeling
as higher baseline systolic blood pressure, suggesting that omechanism of remodeling related to a decrease in load by
ore intense treatment of blood pressure.
Reverse remodeling was identified as an independent
redictor of a composite outcome end point over the
ubsequent long-term follow-up after the second analysis of
V size and function. The novelty of the study revolves
round this point—that the occurrence of favorable reverse
emodeling in response to therapy identifies a subpopulation
f patients who will have a more favorable course over many
ears. The strengths of the study include the seemingly
omogeneous evidence-based treatment strategy at a ter-
iary center and the length of the follow-up, much longer
han most studies.
There are also some limitations. The composite end point
sed by Merlo et al. (20) includes the occurrence of heart
ransplantation, which is an event that certainly incorporates
n unfavorable natural history, but is influenced by many
ther variables. In the multivariable model that included the
ccurrence of reverse remodeling at the follow-up time
oint, other variables were identified that were associated
ith less favorable outcomes, including New York Heart
ssociation functional classes III to IV and moderate to
evere mitral regurgitation, both analyzed at the follow-up
isit at approximately 2 years out. The latter variables may
epresent patients with advanced disease at baseline who did
ot change or patients in whom those features developed
ver the first 2 years of follow-up. Thus, the model is
omplex and included variables that reflect a change from
aseline (LV remodeling), variables that reflect measures at
time point (baseline), and variables that reflect measures at
second time point (the New York Heart Association
unctional class and severity of mitral regurgitation). Per-
aps more straightforward would have been to analyze all
ariables by the degree of change from baseline to follow-up
nd to have included other candidates that may provide
rognostic information, such as changes in renal function.
he patient population in this study included only those
ith nonischemic cardiomyopathy who, in most studies,
end to have more robust responses to therapies affecting
emodeling (21). Thus, how these results and their impli-
ations apply to patients with ischemic cardiomyopathy is
ot clear.
Nonetheless, there are some important messages. The
ata further reinforce the concept that reversal of LV
emodeling in response to therapeutic intervention identifies
group of patients with heart failure and LV dysfunction
ho will have a more favorable long-term course. In
ddition, the data suggest that risk stratification in patients
ith heart failure is a moving target. Baseline variables on
n initial visit can provide a prognostic snapshot, but many
re subject to change during contemporary therapy, and
ignificant reclassification of risk may occur. Larger data-
ases with analysis of changes in key variables may allow
reation of prognostic models that document the magnitude
f reclassification.
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March 29, 2011:1477–9 Ventricular RemodelingFinally, the results also demonstrate once again the
remarkable ability of the left ventricle to adapt (and re-
adapt) to prevailing conditions and that progression and
regression of the processes of LV remodeling are indeed
fundamental to the disease course of patients with heart
failure and systolic LV dysfunction.
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